LENSAR (LNSR) 10-Q 9 Aug 23 2023 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2023	Aug. 02, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	LENSAR, INC.
Entity Central Index Key	0001320350
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		11,246,205
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	LNSR
Security Exchange Name	NASDAQ
Entity File Number	001-39473
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	32-0125724
Entity Address, Address Line One	2800 Discovery Drive
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32826
City Area Code	888
Local Phone Number	536-7271
Document Quarterly Report	true
Document Transition Report	false

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue
Product and service revenue	$ 10,321	$ 6,623	$ 16,944	$ 14,564
Lease	1,691	1,415	3,320	2,814
Total revenue	12,012	8,038	20,264	17,378
Cost of revenue (exclusive of amortization)
Total cost of revenue	5,251	3,146	9,183	7,794
Operating expenses
Selling, general and administrative expenses	7,854	7,569	14,609	13,847
Research and development expenses	1,499	3,834	3,149	8,622
Amortization of intangible assets	275	287	551	596
Operating loss	(2,867)	(6,798)	(7,228)	(13,481)
Other (expense) income
Change in fair value of warrant liabilities	(5,997)		(5,997)
Other income, net	111	39	200	48
Net loss	$ (8,753)	$ (6,759)	$ (13,025)	$ (13,433)
Net loss per common share:
Basic	$ (0.81)	$ (0.67)	$ (1.21)	$ (1.34)
Diluted	$ (0.81)	$ (0.67)	$ (1.21)	$ (1.34)
Weighted-average number of common shares used in calculation of net loss per share:
Basic	10,820	10,073	10,768	10,020
Diluted	10,820	10,073	10,768	10,020
Product
Revenue
Product and service revenue	$ 9,377	$ 5,733	$ 15,035	$ 12,702
Cost of revenue (exclusive of amortization)
Total cost of revenue	3,665	1,765	5,964	4,459
Service
Revenue
Product and service revenue	944	890	1,909	1,862
Cost of revenue (exclusive of amortization)
Total cost of revenue	1,090	897	2,229	2,377
Lease
Cost of revenue (exclusive of amortization)
Total cost of revenue	$ 496	$ 484	$ 990	$ 958

CONDENSED BALANCE SHEETS (Unaud

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 25,466	$ 14,674
Accounts receivable, net of allowance of $30 and $56, respectively	3,223	6,040
Notes receivable, net of allowance of $12 and $4, respectively	595	200
Inventories	18,152	11,740
Prepaid and other current assets	1,728	1,062
Total current assets	49,164	33,716
Property and equipment, net	605	563
Equipment under lease, net	6,159	6,316
Notes and other receivables, long-term, net of allowance of $25 and $9, respectively	1,221	442
Intangible assets, net	11,571	12,122
Other assets	2,476	2,685
Total assets	71,196	55,844
Current liabilities:
Accounts payable	4,619	5,422
Accrued liabilities	4,321	4,700
Deferred revenue	1,067	768
Operating lease liabilities	549	531
Total current liabilities	10,556	11,421
Long-term operating lease liabilities	2,033	2,272
Warrant liabilities	11,602
Other long-term liabilities	568	167
Total liabilities	24,759	13,860
Commitments and contingencies (Note 9)
Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 and no shares authorized at June 30, 2023 and December 31, 2022, respectively; 20 and no shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively; aggregate liquidation preference of $20,000 and $0 at June 30, 2023 and December 31, 2022, respectively	13,747
Stockholders’ equity:
Preferred stock, par value $0.01 per share, 9,980 and 10,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, par value $0.01 per share, 150,000 shares authorized at June 30, 2023 and December 31, 2022; 11,199 and 11,093 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively	112	111
Additional paid-in capital	143,111	139,381
Accumulated deficit	(110,533)	(97,508)
Total stockholders’ equity	32,690	41,984
Total liabilities, convertible preferred stock, and stockholders' equity	$ 71,196	$ 55,844

CONDENSED BALANCE SHEETS (Una_2

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accounts receivable, allowance	$ 30	$ 56
Notes receivable, allowance	12	4
Notes and other receivables, long-term, allowance	$ 25	$ 9
Temporary equity, par value per share	$ 0.01	$ 0.01
Temporary equity, shares authorized	20,000	0
Temporary equity, shares issued	20,000	0
Temporary equity, shares outstanding	20,000	0
Temporary equity, aggregate liquidation preference	$ 20,000	$ 0
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	9,980,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	11,199,000	11,093,000
Common stock, shares outstanding	11,199,000	11,093,000

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities
Net loss	$ (13,025)	$ (13,433)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,158	1,110
Amortization of intangible assets	551	596
Non-cash operating lease cost	267	260
Provision for expected credit losses	(2)	125
Stock-based compensation expense	3,550	3,244
Change in fair value of warrant liabilities	5,997
Changes in operating assets and liabilities:
Accounts receivable	2,844	1,871
Notes receivable	(1,199)	149
Prepaid and other current assets	(666)	470
Inventories	(7,265)	(818)
Accounts payable	(804)	1,497
Accrued liabilities	(668)	(232)
Other	422	(236)
Net cash used in operating activities	(8,840)	(5,397)
Cash flows from investing activities
Purchase of property and equipment	(189)	(56)
Net cash used in investing activities	(189)	(56)
Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of offering costs	14,035
Proceeds from issuance of warrants	5,605
Proceeds from issuance of common stock under employee stock purchase plan	181	212
Payment of contingent consideration		(1,200)
Net cash provided by (used in) financing activities	19,821	(988)
Net increase (decrease) in cash and cash equivalents	10,792	(6,441)
Cash and cash equivalents at beginning of the period	14,674	31,637
Cash and cash equivalents at end of the period	25,466	25,196
Supplemental cash flow information
Cash paid for taxes	18	10
Supplemental schedule of non-cash investing and financing activities
Transfer from Inventories to Equipment under lease, net	1,281	1,416
Transfer from (to) Inventories to (from) Property and equipment, net	(428)	$ 34
Accrued offering costs	$ (289)

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Series A Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2021	$ 54,879		$ 110	$ 132,363	$ (77,594)
Beginning Balance, Shares at Dec. 31, 2021			10,990,000
Stock-based compensation	1,607			1,607
Restricted stock awards cancelled			(5,000)
Net loss	(6,674)				(6,674)
Ending Balance at Mar. 31, 2022	49,812		$ 110	133,970	(84,268)
Ending Balance, Shares at Mar. 31, 2022			10,985,000
Beginning Balance at Dec. 31, 2021	54,879		$ 110	132,363	(77,594)
Beginning Balance, Shares at Dec. 31, 2021			10,990,000
Net loss	(13,433)
Ending Balance at Jun. 30, 2022	44,902		$ 110	135,819	(91,027)
Ending Balance, Shares at Jun. 30, 2022			11,021,000
Beginning Balance at Mar. 31, 2022	49,812		$ 110	133,970	(84,268)
Beginning Balance, Shares at Mar. 31, 2022			10,985,000
Stock-based compensation	1,637			1,637
Issuance of common stock under the 2020 ESPP	212			212
Issuance of common stock under the 2020 ESPP, Shares			37,000
Restricted stock awards cancelled			(1,000)
Net loss	(6,759)				(6,759)
Ending Balance at Jun. 30, 2022	44,902		$ 110	135,819	(91,027)
Ending Balance, Shares at Jun. 30, 2022			11,021,000
Beginning Balance at Dec. 31, 2022
Beginning Balance, Shares at Dec. 31, 2022	0
Beginning Balance at Dec. 31, 2022	$ 41,984		$ 111	139,381	(97,508)
Beginning Balance, Shares at Dec. 31, 2022			11,093,000
Stock-based compensation	1,726			1,726
Issuance of common stock, Shares			15,000
Restricted stock awards cancelled			(5,000)
Net loss	(4,272)				(4,272)
Ending Balance at Mar. 31, 2023		$ 0
Ending Balance, Shares at Mar. 31, 2023		0
Ending Balance at Mar. 31, 2023	39,438		$ 111	141,107	(101,780)
Ending Balance, Shares at Mar. 31, 2023			11,103,000
Beginning Balance at Dec. 31, 2022
Beginning Balance, Shares at Dec. 31, 2022	0
Beginning Balance at Dec. 31, 2022	$ 41,984		$ 111	139,381	(97,508)
Beginning Balance, Shares at Dec. 31, 2022			11,093,000
Net loss	(13,025)
Ending Balance at Jun. 30, 2023	$ 13,747
Ending Balance, Shares at Jun. 30, 2023	20,000	20,000
Ending Balance at Jun. 30, 2023	$ 32,690	$ 13,747	$ 112	143,111	(110,533)
Ending Balance, Shares at Jun. 30, 2023			11,199,000
Beginning Balance at Mar. 31, 2023		$ 0
Beginning Balance, Shares at Mar. 31, 2023		0
Beginning Balance at Mar. 31, 2023	39,438		$ 111	141,107	(101,780)
Beginning Balance, Shares at Mar. 31, 2023			11,103,000
Stock-based compensation	1,824			1,824
Issuance of Series A Redeemable Convertible Preferred Stock, net of offering costs		$ 13,747
Issuance of Series A Convertible Preferred Stock, net of offering costs, Shares		20,000
Issuance of common stock under the 2020 ESPP	181		$ 1	180
Issuance of common stock under the 2020 ESPP, Shares			71,000
Issuance of common stock under the 2020 Plan			$ (1)
Issuance of common stock under the 2020 Plan, Shares			26,000
Net loss	(8,753)				(8,753)
Ending Balance at Jun. 30, 2023	$ 13,747
Ending Balance, Shares at Jun. 30, 2023	20,000	20,000
Ending Balance at Jun. 30, 2023	$ 32,690	$ 13,747	$ 112	$ 143,111	$ (110,533)
Ending Balance, Shares at Jun. 30, 2023			11,199,000

CONDENSED STATEMENTS OF CHANG_2

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2023 USD ($)
Series A Redeemable Convertible Preferred Stock
Offering costs	$ 649

Overview and Basis of Presentat

Overview and Basis of Presentation	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview and Basis of Presentation	Note 1. Overview and B asis of Presentation Overview and Organization LENSAR, Inc. (“LENSAR” or the “Company”) is a global medical device business focused on the design, development and commercialization of advanced technology for the treatment of cataracts and management of astigmatism to achieve improved visual outcomes for patients. The Company is a public company whose stock is listed and trading under the symbol “LNSR” on The Nasdaq Stock Market LLC (“Nasdaq”). The Company’s revenue is derived from the sale and lease of the Company’s laser systems, which may include equipment, a consumable referred to as the Patient Interface Device (“PID”), procedure licenses, training, installation, limited warranty and maintenance agreements through extended warranty. The Company has developed its next-generation ALLY® Adaptive Cataract Treatment System (“ALLY System”), which combines all of the features from the LENSAR Laser System with a dual-pulse laser, integrated in a small, compact cataract treatment system that is designed to allow surgeons to perform a sterile femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. The ALLY System, which has received clearance from the U.S. Food and Drug Administration (“FDA”), enables cataract surgeons to complete the femtosecond-laser-assisted cataract surgery (“FLACS”) procedure in a single, sterile environment. The Company executed a controlled and targeted initial launch of the ALLY System beginning in August 2022. The ALLY System is now available to U.S. cataract surgeons and has also received regulatory clearance in India. In addition, the Company submitted the ALLY System for certification in the European Union, or EU, in September 2022 and, in 2023, submitted documentation to distributors in South Korea, Taiwan, and the Philippines for additional marketing or certification applications outside the United States. This is the first step in an effort to commercialize the ALLY System in additional countries and operating regions. The Company has incurred recurring losses and operating cash outflows since its inception and, as of June 30, 2023, had an accumulated deficit of $ 110,533 . The Company expects to continue to incur losses and cash outflows from operating activities for the near-term future. In addition, the Company’s results of operations, financial condition and cash flows have been adversely affected by the COVID-19 pandemic, including supply chain shortages, inflationary pressures and price increases that originated during the pandemic. The Company has experienced some supply chain disruptions and increased costs or unavailability of various component parts needed for the development and supply of the ALLY System originally connected with the COVID-19 pandemic, including increasing lead times required for the ordering of component parts to meet targeted production goals and unpredictability with respect to the availability and delivery timing of these parts. The extent to which the COVID-19 outbreak, and current or future variants, will further negatively impact the Company’s business or operating results cannot be determined with certainty at this time. To date, the Company has maintained sufficient inventory to mitigate significant adverse impact from such disruptions and unavailability in the near-term and to facilitate the launch of the ALLY System. If supply chain shortages and disruptions continue or worsen, or the Company is unable to find suitable alternative component parts, there is no guarantee the Company will be able to meet customer demand for the ALLY System following its launch. In addition, pricing increases in component parts for the ALLY System resulting from inflationary pressures and related macroeconomic conditions may necessitate an increase in overall cost to customers, which in turn may have an adverse impact on customer demand. Management believes the Company’s cash and cash equivalents on hand, together with cash generated from the future sale and lease of products, will provide sufficient funds for its operating, investing, and financing cash flows for a period of at least twelve months from the date of issuance of these financial statements. With the commercial launch of the ALLY System, the Company expects annual revenue and selling, general and administrative expenses to increase from current levels. In addition, the successful commercialization of the ALLY System depends in part on the Company’s ability to produce the ALLY System in sufficient quantities, within requested timelines and at an acceptable price to satisfy customer demand. The Company’s liquidity needs will be largely determined by the Company’s ability to successfully commercialize its products and the progression, additional regulatory clearances or certifications and launch of the ALLY System in additional jurisdictions in the future. Such success will depend in part on the availability of the necessary component parts for the ALLY System. In the future, the Company may need to raise additional capital through equity or debt financings, borrowings under credit facilities or from other sources in the future. The Company may issue securities, including common stock, preferred stock, warrants, and/or debt securities through private placement transactions or registered public offerings in the future. The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of the Company’s control, and the Company may be unable to raise financing when needed, or on terms favorable to the Company. If the necessary funds are not available from these sources, the Company may have to delay, reduce or suspend the scope of its sales and marketing efforts, research and development activities, or other components of its operations. Basis of Presentation These condensed financial statements of the Company are unaudited and have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim financial information and, therefore, omit or condense certain footnotes and other information normally included. The condensed financial statements include all adjustments (consisting only of normal recurring adjustments) that management of the Company believes are necessary for a fair statement of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year. The December 31, 2022 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The accompanying unaudited condensed financial statements and related financial information should be read in conjunction with the Company’s annual audited financial statements and the related notes thereto for the fiscal year ended December 31, 2022 , included in the Annual Report on Form 10-K (the “Annual Report”) as filed with the SEC.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Other than policies noted below, there have been no significant changes to the significant accounting policies disclosed in Note 2, Summary of Significant Accounting Policies , of the annual audited financial statements included in the Annual Report. Accounting Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes to the condensed financial statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include, but are not limited to, revenue recognition and allowance for expected credit losses, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, operating lease right-of-use assets and liabilities, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrant liabilities. Management evaluates its estimates on an ongoing basis as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates. The COVID-19 pandemic and global macroeconomic conditions originating during the pandemic continue to directly and indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances. The Company continues to monitor developments that are highly uncertain, including supply chain disruptions and price increases, as well as the economic impact on domestic and international suppliers, customers, and markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, its current expected credit losses, the carrying value of the Company's intangible assets and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2023 and through the date of this report. As a result of these assessments, there were no impairments or material increases in expected credit losses or valuation allowances that impacted the Company's condensed financial statements as of and for the three and six months ended June 30, 2023 and 2022. However, the Company's future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the condensed financial statements in future reporting periods. As of the date of issuance of these unaudited condensed interim financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Derivative Financial Instruments The Company evaluates financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed statements of operations. Warrants issued by the Company that do not meet the criteria for equity treatment are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes. Fair Value Measurement The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or the Company paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories: • Level 1—based on quoted market prices in active markets for identical assets and liabilities. • Level 2—based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. Fair value measurements are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The following table sets forth by level, within the fair value hierarchy, the Company's assets and liabilities at fair value as of June 30, 2023: June 30, 2023 Level 1 Level 2 Level 3 Total Assets $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities Warrant derivative liabilities $ — $ — $ 11,602 $ 11,602 Total liabilities $ — $ — $ 11,602 $ 11,602 There were no assets or liabilities measured at fair value as of June 30, 2022. The change in fair value of warrant liabilities measured on a recurring basis using unobservable Level 3 inputs for the quarter ended June 30, 2023 is set forth below: Fair Value at May 18, 2023 Change in Fair Value Fair Value at June 30, 2023 Series A Warrant $ 2,971 $ 3,085 $ 6,056 Series B Warrant 2,634 2,912 5,546 Total warrant liabilities $ 5,605 $ 5,997 $ 11,602 The carrying value of the Company’s cash, cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate fair value based on the short-term maturities of these instruments. The carrying value of the Company’s notes receivable also approximates fair value based on the associated credit risk. There have been no transfers between levels. Income Taxes Income tax expense/(benefit) from continuing operations for the three and six months ended June 30, 2023 and 2022 was $ 0 in each period, which resulted primarily from maintaining a full valuation allowance against the Company’s deferred tax assets. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss and tax credit carryforwards that may be used in future years. The Company has not completed an analysis to determine whether any such limitations have been triggered as of June 30, 2023, however, the Company notes that the Securities Purchase Agreement may have an impact on ownership for purposes of this analysis. Until a study is completed and any limitation known, the Company will not make adjustments to its deferred tax assets. Due to the existence of the valuation allowance, future changes in the Company’s deferred taxes will not impact its effective tax rate or balance sheet. Recently Issued Accounting Pronouncements Not Yet Adopted The Company reviewed recent pronouncements issued by the FASB and other authoritative standards groups with future effective dates and concluded the pronouncements are either not applicable to the Company or are not expected to have a material impact on the Company’s financial position or results of operations.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 3. Revenue from Contracts with Customers Disaggregation of Revenue The following table summarizes the Company’s product and service revenue disaggregated by geographic region, which is determined based on customer location, for the three and six months ended June 30, 2023 and 2022: Three Months Ended Six Months Ended 2023 2022 2023 2022 United States $ 7,105 $ 4,097 $ 11,369 $ 8,067 South Korea 16 662 25 2,096 Europe 1,983 956 3,521 2,575 Asia (excluding South Korea) 1,128 771 1,836 1,551 Other 89 137 193 275 Total 1 $ 10,321 $ 6,623 $ 16,944 $ 14,564 1. The table above does not include lease revenue of $ 1,691 and $ 1,415 for three months ended June 30, 2023 and 2022, respectively, and $ 3,320 and $ 2,814 for the six months ended June 30, 2023 and 2022, respectively. Substantially all lease revenue originates from the United States. Refer to Note 5, Leases . Contract Balances The following table provides information about receivables and contract liabilities from contracts with customers: Classification As of As of Accounts receivable, current Accounts receivable, net $ 3,223 $ 6,040 Notes receivable, current Notes receivable, net $ 595 $ 200 Notes receivable, long-term Notes and other receivables, long-term, net $ 1,221 $ 442 Contract asset, current Prepaid and other current assets $ 825 $ 332 Deferred revenue, current Deferred revenue $ 1,067 $ 768 Deferred revenue, non-current Other long-term liabilities $ 343 $ 17 Contract liability, long-term Other long-term liabilities $ 223 $ 150 Accounts Receivables, Net – Accounts receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. Most customers are on pre-paid or 30 -day payment terms, depending on the product purchased. The Company maintains an allowance for expected credit losses to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer credit worthiness, historical payment experience, the age of outstanding receivables, collateral to the extent applicable and reflects the possible impact of current conditions and reasonable forecasts not already reflected in historical loss information. The following table summarizes the activity in the allowance for accounts receivable: Amount Accounts receivable, allowance for credit losses as of $ 56 Provision for credit losses ( 26 ) Write-offs — Accounts receivable, allowance for credit losses as of $ 30 Accounts receivable, allowance for credit losses as of $ 47 Provision for credit losses ( 6 ) Write-offs ( 16 ) Accounts receivable, allowance for credit losses as of $ 25 Notes Receivables, Net – Notes receivable, net includes amounts billed and due from customers under extended payment terms with a significant financing component. Interest rates on notes receivable range from 5.0 % to 7.0 %. The Company recorded interest income on notes receivable during the three months ended June 30, 2023 and 2022 of $ 20 and $ 3 , respectively, and during the six months ended June 30, 2023 and 2022 of $ 32 and $ 8 , respectively, in other income, net in the statement of operations. The following table summarizes the activity in the allowance for notes receivable: Amount Notes receivable, allowance for credit losses as of $ 13 Provision for credit losses 24 Write-offs — Notes receivable, allowance for credit losses as of $ 37 Notes receivable, allowance for credit losses as of $ 63 Provision for credit losses 130 Write-offs ( 11 ) Notes receivable, allowance for credit losses as of $ 182 Contract Assets – The Company's contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company's condensed balance sheets. The following table provides information about contract assets from contracts with customers: Amount Contract assets as of December 31, 2022 $ 332 Contract assets recognized 889 Payments received ( 250 ) Write-off due to contract modification ( 146 ) Contract assets as of June 30, 2023 $ 825 Contract Liabilities – The Company’s contract liabilities represent services and products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies contract liabilities as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of contract liabilities is included in other long-term liabilities in the Company’s condensed balance sheets. The following table provides information about contract liabilities from contracts with customers: Amount Contract liabilities as of December 31, 2022 $ 935 Billings not yet recognized as revenue 1,324 Beginning contract liabilities recognized as revenue ( 626 ) Contract liabilities as of June 30, 2023 $ 1,633 Contract liabilities as of December 31, 2021 $ 970 Billings not yet recognized as revenue 637 Beginning contract liabilities recognized as revenue ( 633 ) Contract liabilities as of June 30, 2022 $ 974 Transaction Price Allocated to Future Performance Obligations At June 30, 2023 , the revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more was approximately $ 15,705 . The Company expects to satisfy its remaining performance obligations by December 31, 2029, with $ 3,155 to be satisfied by December 31, 2023 , $ 4,704 to be satisfied by December 31, 2024 , $ 3,687 to be satisfied by December 31, 2025 , $ 2,194 to be satisfied by December 31, 2026 , $ 1,361 to be satisfied by December 31, 2027 , $ 486 to be satisfied by December 31, 2028 , and $ 118 to be satisfied thereafter . The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected lengths of one year or less or (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for the products delivered or services performed.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	Note 4. Inventories Inventory balances were as follows: As of As of Finished Goods $ 6,303 $ 4,002 Work-in-process 2,753 797 Raw Materials 9,096 6,941 Total $ 18,152 $ 11,740

Leases

Leases	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Leases	Note 5. Leases Lessor Arrangements The Company has operating leases systems. The Company’s leases have remaining lease terms of less than one year to six years . Lease revenue for the three and six months ended June 30, 2023 and 2022 was as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Lease revenue $ 1,691 $ 1,415 $ 3,320 $ 2,814

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 6. Intangible Assets The components of intangible assets were as follows: As of June 30, 2023 As of December 31, 2022 Gross Accumulated Net Gross Accumulated Net Finite-lived intangible assets: Customer relationships 1,2 $ 4,292 $ ( 2,196 ) $ 2,096 $ 4,292 $ ( 2,028 ) $ 2,264 Acquired technology 1,3,4 13,900 ( 4,425 ) 9,475 13,900 ( 4,042 ) 9,858 Acquired trademarks 1 570 ( 570 ) — 570 ( 570 ) — $ 18,762 $ ( 7,191 ) $ 11,571 $ 18,762 $ ( 6,640 ) $ 12,122 1. Certain intangible assets were established upon PDL BioPharma, Inc.’s acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a period of 15 years. The intangible assets for customer relationships are amortized on a straight-line basis or a double declining basis over their estimated useful lives up to 20 years based on the method that better represents the economic benefits to be obtained. 2. LENSAR acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which are being amortized on a straight-line basis over a period of 10 years. 3. LENSAR acquired certain intangible assets from a medical technology company in an asset acquisition, which are being amortized on a straight-line basis over a period of 15 years. 4. In 2019, LENSAR acquired certain intellectual property from a third party. Pursuant to the Company's agreement with the third party, the Company made milestone payments of $ 2,400 during the year ended December 31, 2022. The intangible assets will be amortized on a straight-line basis over a period of 15 years. Amortization expense for three months ended June 30, 2023 and 2022 was $ 275 and $ 287 , respectively, and for the six months ended June 30, 2023 and 2022 was $ 551 and $ 596 , respectively. Based on the intangible assets recorded at June 30, 2023, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows: Fiscal Year Amount Remainder of 2023 546 2024 1,125 2025 1,234 2026 1,224 2027 1,215 2028 1,008 Thereafter 5,219 Total remaining estimated amortization expense $ 11,571

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following: As of As of Compensation $ 2,369 $ 3,348 Professional services 562 437 Customer advances 90 171 Warranty 184 120 Accrued offering costs 401 — Other 715 624 Total $ 4,321 $ 4,700

Warrant Liabilities

Warrant Liabilities	6 Months Ended
	Jun. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrant Liabilities	Note 8. Warrant Liabilities In May 2023, the Company completed the Private Placement (as defined below), which included the issuance of warrants (the “Warrants”) to purchase an aggregate of 4,367 shares of common stock (the “Warrant Shares”). Fifty percent of the Warrants have an exercise price equal to $ 2.45 per share (the “Series A Warrant”), and 50 % of the Warrants have an exercise price equal to $ 3.0625 per share (the “Series B Warrant”), subject in each instance to adjustments as provided under the terms of the Warrants. Refer to Note 10, Redeemable Convertible Preferred Stock , for more details related to the Private Placement. Upon the occurrence of certain transactions (“Fundamental Transactions,” as defined below), the Warrants provide that they are redeemable by the holder thereof for a value determined using a Black Scholes option pricing model with inputs calculated as described in the applicable Warrant, which includes a 100 % floor on the volatility input to be utilized. The Company has determined that this provision introduces leverage to the holders of the Warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Accordingly, pursuant to ASC 815, the Company classified the fair value of the Warrants as a liability to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. Of the $ 20,000 gross proceeds for the Private Placement, $ 5,605 was allocated to the Warrants and the remaining $ 14,395 was allocated to the Series A Redeemable Convertible Preferred Stock. The Company estimated the fair value of the warrant liabilities using recently quoted market prices of the Company's common stock and the Black-Scholes option pricing model. The fair value of the warrant liabilities was estimated using the following assumptions for the three and six months ended June 30, 2023 and 2022: June 30, 2023 May 18, 2023 Risk-free interest rate 4.1 % 3.7 % Expected term (years) 4.9 5.0 Expected volatility 55 % 55 % Dividends 0.0 % 0.0 % Expected term : The expected term for the warrant liabilities was based on the remaining contractual term of the Warrants. Risk-free interest rate : The risk-free interest rate was based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected term. Expected volatility : The expected volatility for the warrant liabilities was based on an index of the historical volatilities of a group of comparable publicly-traded medical device and other peer companies, which the Company believed was representative of the volatility of its common stock. Expected dividend yield : The Company does not intend to pay dividends for the foreseeable future. Accordingly, the Company used a dividend yield of zero in the assumptions.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Purchase Obligation LENSAR is a party to various supply agreements for the manufacture and supply of certain components. The supply agreements commit LENSAR to a minimum purchase obligation of approximately $ 8,959 over the next 18 months. LENSAR expects to meet these requirements. Royalty Payments The Company acquired certain intellectual property, which would result in royalty payments at a rate of 3 % of certain revenue upon the phacoemulsification features being cleared for commercialization and operational in the ALLY System. Employee Retention Credit In March 2020, the United States enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act provides for an employee retention credit (“ERC”), which is a refundable tax credit against certain employment taxes paid in 2020 and 2021. The Company filed for the ERC in the amount of approximately $ 1,600 in the first quarter of 2023. Should the Company receive the full ERC, it will owe $ 250 in contingent professional fees. Given the uncertainty the ERC will be allowed by the Internal Revenue Service and the amount received, if any, cannot be estimated, the Company has no t recognized any amounts in the condensed financial statements as of June 30, 2023. Refer to Note 15, Subsequent Event . Legal Matters The medical device market in which LENSAR participates is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. The Company makes provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. From time to time, we may become involved in various legal proceedings relating to matters incidental to the ordinary course of our business, including intellectual property, commercial, product liability, employment, class action, whistleblower and other litigation and claims, and governmental and other regulatory investigations and proceedings. In addition, on June 26, 2023, a stockholder of the Company filed a complaint against the Company and certain of its officers and members of the board of directors (“Defendants”) in the United States District Court for Delaware, captioned Schaper v. LENSAR, Inc., et al., Case No. 1:23-cv-00692-GBW (the “Schaper Action”). Defendants moved on July 17, 2023 to dismiss the complaint. On July 27, 2023, the parties filed a stipulation extending Schaper’s time to respond to the motion to dismiss. Pursuant to the stipulation, Schaper is required to file an amended complaint on or before August 14, 2023. The Company vigorously denies that the definitive proxy statement filed with the SEC on June 20, 2023 was deficient in any respect. The Company believes the allegations and claims asserted in the Schaper Action are without merit and that supplemental disclosures were not required or necessary under applicable laws. At this time, the Company cannot predict the outcome, or provide a reasonable estimate or range of estimates of the possible outcome or loss, if any, in this matter. This matter or other such matters may be time-consuming, divert management’s attention and resources, cause us to incur significant expenses or liability or require us to change our business practices, even if we believe the claims asserted against us are without merit. Because of the potential risks, expenses and uncertainties of litigation, we may, from time to time, settle disputes, even where we believe that we have meritorious claims or defenses. Because litigation is inherently unpredictable, we cannot assure you that the results of any such actions will not have a material adverse effect on our business, results of operations, financial condition or cash flows.

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	6 Months Ended
	Jun. 30, 2023
Disclosure Convertible Preferred Stock [Abstract]
Redeemable Convertible Preferred Stock	Note 10. Redeemable Convertible Preferred Stock Series A Redeemable Convertible Preferred Stock In May 2023, the Company entered into a Securities Purchase Agreement (the “SPA”) with NR-GRI Partners, LP (“NR-GRI”), whereby it sold to NR-GRI, for an aggregate purchase price of $ 20,000 , 20 shares of Series A Redeemable Convertible Preferred Stock and the Warrants (the “Private Placement”). Refer to Note 8, Warrant Liabilities , for more details related to the Warrants. The Series A Redeemable Convertible Preferred Stock is convertible into 7,940 shares of common stock at the election of NR-GRI. On August 1, 2023, the Company’s stockholders voted to approve the issuance of shares of the Company’s common stock issuable upon conversion of the shares of Series A Redeemable Convertible Preferred Stock and exercise of the Warrants. As a result of the stockholders’ approval of the Private Placement, applicable ownership limitations under Nasdaq rules were lifted, and NR-GRI became entitled to convert shares of Series A Redeemable Convertible Preferred Stock or exercise Warrants up to the full amount purchased in the Private Placement. Holders of Series A Redeemable Convertible Preferred Stock are entitled to vote on an as-converted basis with holders of common stock. The Series A Redeemable Convertible Preferred Stock ranks senior to the common stock as to distributions and payments upon the liquidation, dissolution and winding up of the Company, and holders of Series A Redeemable Convertible Preferred Stock participate with the holders of the common stock on an as-converted basis to the extent any dividends are declared on common stock. The shares of Series A Redeemable Convertible Preferred Stock will automatically be redeemed in connection with certain transactions (“Fundamental Transactions”), including a merger, sale of all or substantially all the assets of the Company, recapitalization, or the sale by the Company of shares resulting in more than 50 % ownership by a person or group. In such event, the redemption price would be equal to the greater of the stated value of the shares of Series A Redeemable Convertible Preferred Stock or the consideration per share of common stock in the Fundamental Transaction (or in the absence of such consideration, the volume-weighted average price of the Company’s common stock immediately preceding the closing of the Fundamental Transaction). The Series A Redeemable Convertible Preferred Stock is classified as temporary equity in the condensed balance sheet because redemption automatically occurs upon a Fundamental Transaction. However, redemption is not considered probable; therefore, the Series A Redeemable Convertible Preferred Stock is not accreted to face value. The proceeds of the transaction were allocated first to the fair value of warrants due to the classification of the warrants as a liability on the condensed balance sheet and the remainder of the proceeds were allocated to the Series A Redeemable Convertible Preferred Stock. Offering costs of $ 901 were allocated ratably based on the allocation of proceeds; $ 253 was allocated to the general and administrative expenses and $ 648 was allocated to Series A Redeemable Convertible Preferred Stock. Series A Redeemable Convertible Preferred Stock is presented net of offering costs on the condensed balance sheet. In connection with the parties’ entry into the SPA, the Company and NR-GRI entered into a Registration Rights Agreement, pursuant to which the Company filed a resale registration statement on Form S-3 (No. 333-272930) with respect to the resale of the shares of the Company’s common stock issuable upon conversion of the shares of Series A Redeemable Convertible Preferred Stock and exercise of the Warrants.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Stockholders' Equity	Note 11. Stockholders’ Equity Common Stock The Company has a single class of common stock in which stockholders are entitled to one vote for each share of common stock . No cash dividend was declared on common stock during the three and six months ended June 30, 2023 and 2022. The Company currently has an effective shelf registration statement on Form S-3 (No. 333-255136), which was filed with the SEC on April 8, 2021 (the “Registration Statement”), under which the Company may offer from time to time in one or more offerings any combination of common and preferred stock, debt securities, depositary shares, warrants, purchase contracts and units of up to $ 100.0 million in the aggregate. The Company also simultaneously entered into a sales agreement providing for the offering, issuance and sale by the Company of up to an aggregate $ 35.0 million of its common stock from time to time in “at-the-market” (“ATM”) offerings under the Registration Statement. No shares were sold under the ATM during the three and six months ended June 30, 2023 and 2022.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 12. Stock-Based Compensation Stock-Based Incentive Plans The 2020 Plan In July 2020, the Board of Directors approved the LENSAR Inc. 2020 Incentive Award Plan (the “2020 Plan”). The 2020 Plan provides for the grant of stock options, restricted stock, restricted stock unit awards and other stock-based awards to recipients. The amount and terms of grants are determined by the Company’s Board of Directors or a duly authorized committee thereof. Participants must pay the Company, or make provisions to pay, any required withholding taxes by the date of the event creating the tax liability. Participants may satisfy the tax liability in cash or in stock. A total of 3,333 shares of common stock were initially reserved for issuance pursuant to the 2020 Plan. The number of shares available for issuance under the 2020 Plan includes an annual increase on the first day of each fiscal year beginning fiscal 2021, equal to the lesser of (i) 5 % of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of shares as determined by the Board of Directors. As of June 30, 2023 , the Company has reserved a total of 4,984 shares of common stock for issuance under the 2020 Plan. A summary of the shares available for issuance under the 2020 Plan is as follows: Number of Shares Balance at December 31, 2022 1,002 Authorized 555 Granted/Awarded ( 1,368 ) Cancelled 68 Balance at June 30, 2023 257 Stock Options The exercise price of incentive stock options (“ISOs”) and nonqualified stock options (“NSOs”) shall not be less than 100 % of the fair market value on the grant date of the option and the term may not exceed 10 years. The exercise price of ISOs granted to a 10 % stockholder shall not be less than 110 % of the estimated fair market value on the grant date of the option and the term may not exceed five years . To date, options have a term of 10 years and generally vest over one to four years from the grant date. Option award activity under the 2020 Plan is set forth below: Options Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding at December 31, 2022 1,202 $ 6.91 8.7 $ — Options granted 826 $ 2.97 Options exercised — $ — Options cancelled ( 32 ) $ 5.60 Outstanding at June 30, 2023 1,996 $ 5.30 8.8 $ 1,037 Vested and expected to vest at June 30, 2023 1,996 $ 5.30 8.8 $ 1,037 Vested and exercisable at June 30, 2023 710 $ 7.01 8.1 $ 23 The weighted average grant date fair value of options granted during the three and six months ended June 30, 2023 was $ 2.10 and $ 1.94 , respectively. The total fair value of options vested during the three and six months ended June 30, 2023 was approximately $ 604 and $ 1,794 , respectively. Total unrecognized compensation expense of $ 3,409 related to stock options will be recognized over a weighted average period of 2.3 years. The following table summarizes information about stock options outstanding and vested as of June 30, 2023: Options Outstanding Options Vested Exercise Price Options Outstanding Weighted Average Remaining Contractual Term (in Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 2.52 - $ 3.10 360 9.5 $ 2.66 — $ — $ 3.23 455 9.9 $ 3.23 22 $ 3.23 $ 4.86 - $ 5.95 27 9.0 $ 5.75 4 $ 5.95 $ 6.04 418 8.5 $ 6.04 148 $ 6.04 $ 6.07 - $ 8.62 736 7.9 $ 7.44 536 $ 7.44 1,996 8.8 $ 5.30 710 $ 7.01 The Company estimated the fair value of stock-options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options was estimated using the following assumptions for the three and six months ended June 30, 2023 and 2022: Three Months Ended Six Months Ended 2023 2022 2023 2022 Risk-free interest rate 3.5 - 3.9 % 2.5 - 3.0 % 3.5 - 4.2 % 1.5 - 3.0 % Expected term (years) 6 6 6 6 Expected volatility 70 % 70 % 70 % 70 % Dividends 0.0 % 0.0 % 0.0 % 0.0 % Expected term : The expected term for the Company’s stock-based compensation awards was based on an index of the expected terms of a group of comparable publicly-traded medical device and other peer companies, which the Company believed was representative of the expected term of its awards. Risk-free interest rate : The risk-free interest rate was based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected term. Expected volatility : The expected volatility for the Company’s stock-based compensation awards was based on an index of the historical volatilities of a group of comparable publicly-traded medical device and other peer companies, which the Company believed was representative of the volatility of its common stock. Expected dividend yield : The Company does not intend to pay dividends for the foreseeable future. Accordingly, the Company used a dividend yield of zero in the assumptions. Restricted Stock Awards Restricted stock has the same rights as other issued and outstanding shares of the Company’s common stock. The compensation expense related to these awards is determined using the fair market value of the Company’s common stock on the date of the grant. Under the Company’s restricted stock plans, restricted stock awards typically vest over three years and compensation expense associated with these awards is recognized on a straight-line basis over the vesting period. Restricted stock award activity under the 2020 Plan is set forth below: Restricted Stock Awards Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2022 622 $ 10.29 Restricted stock awards granted — $ — Restricted stock awards vested ( 373 ) $ 10.20 Restricted stock awards cancelled ( 6 ) $ 10.81 Non-vested at June 30, 2023 243 $ 10.42 The total fair value of restricted stock awards vested during the three and six months ended June 30, 2023 was approximately $ 1,387 and $ 3,806 , respectively. At June 30, 2023 there was approximately $ 498 of total unrecognized compensation expense related to restricted stock awards, which is expected to be recognized over a weighted-average period of 0.1 years. The number of restricted stock awards that are expected to vest are as follows: 168 in the quarter ending September 30, 2023 and 75 in the quarter ending December 31, 2023. These are based on restricted stock awards outstanding at June 30, 2023 and assumes the requisite service period is fulfilled for all awards outstanding. Actual vesting in future periods may vary from those reflected above. Restricted Stock Units Restricted stock units granted to employees and non-employees generally vest over one to four years in annual equal increments. The fair value of restricted stock units is based on the Company’s closing stock price on the date of grant. Restricted stock unit activity under the 2020 Plan is set forth below: Restricted Stock Units Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2022 86 $ 6.33 Restricted stock units granted 542 $ 2.73 Restricted stock units vested ( 41 ) $ 6.65 Restricted stock units cancelled ( 30 ) $ 2.65 Non-vested at June 30, 2023 557 $ 3.00 The total fair value of restricted stock units vested during the three and six months ended June 30, 2023 was approximately $ 180 and $ 271 , respectively. At June 30, 2023 there was approximately $ 1,350 of total unrecognized compensation expense related to restricted stock units, which is expected to be recognized over a weighted-average period of 1.7 years. 2020 Employee Stock Purchase Plan In September 2020, the Board of Directors approved the LENSAR, Inc. 2020 Employee Stock Purchase Plan (the “2020 ESPP”), under which eligible employees are permitted to purchase common stock at a discount through payroll deductions. A total of 340 shares of common stock were initially reserved for issuance. The number of shares available for issuance under the 2020 ESPP includes an increase on the first day of each fiscal year, beginning in 2022, by an amount equal to the lesser of (i) 1.0 % of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (ii) a lesser amount as determined by the Board of Directors. As of June 30, 2023 , the Company has reserved 451 shares of common stock for issuance under the 2020 ESPP. The price of the common stock purchased will be the lower of 85 % of the fair market value of the common stock at the beginning of an offering period or at the end of a purchase period. The 2020 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the Internal Revenue Code of 1986. As of June 30, 2023 , 235 shares of common stock have been issued to employees participating in the 2020 ESPP and 216 shares were available for future issuance under the 2020 ESPP. The grant date fair value of the shares to be issued under the Company’s 2020 ESPP was estimated using the Black-Scholes valuation model. The following table sets forth the total stock-based compensation expense recognized under the 2020 Plan and the 2020 ESPP in the Company's condensed statements of operations: Three Months Ended Six Months Ended 2023 2022 2023 2022 Cost of revenue – product $ 87 $ 54 $ 170 $ 106 Cost of revenue – service 50 32 96 62 Selling, general and administrative expenses 1,498 1,397 2,924 2,774 Research and development expenses 189 154 360 302 Total $ 1,824 $ 1,637 $ 3,550 $ 3,244 Total unrecognized stock-based compensation expense is expected to be amortized as follows: Fiscal Year Amount Remainder of 2023 $ 1,910 2024 2,124 2025 1,005 2026 213 2027 5 Total unrecognized stock-based compensation expense $ 5,257 The amounts included in this table are based on restricted stock awards, restricted stock units, and stock options outstanding at June 30, 2023 and assumes the requisite service period is fulfilled for all awards outstanding. Actual stock-based compensation expense in future periods may vary from those reflected in the table.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Share	Note 13. Net Loss per Share The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted net loss per share calculations: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net loss $ ( 8,753 ) $ ( 6,759 ) $ ( 13,025 ) $ ( 13,433 ) Weighted average number of shares of common stock 10,820 10,073 10,768 10,020 Basic and diluted net loss per common share $ ( 0.81 ) $ ( 0.67 ) $ ( 1.21 ) $ ( 1.34 ) The Company’s basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. The change in fair value of warrant liabilities of $ 5,997 had a significant impact, and was a significant component, of net loss in the three and six months ended June 30, 2023. As the Company has reported a net loss for all periods presented, basic and diluted net loss per share attributable to common stockholders are the same for those periods. The Company excluded the following amounts of equity securities from its net loss per diluted share calculations for the periods presented because their effect was anti-dilutive: Three and Six Months Ended June 30, 2023 2022 Series A Redeemable Convertible Preferred Stock 7,940 — Series A and Series B Warrants 4,367 — Restricted stock awards and units 800 934 Outstanding stock options 1,996 1,193 The anti-dilutive weighted average shares excluded from the diluted net loss per share diluted shares calculations were:

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 14. Related Party Transactions In May 2023, the Company completed the Private Placement with NR-GRI, an affiliate of North Run Capital, LP (“North Run”). Pursuant to the terms of the Private Placement, Thomas B. Ellis and Todd B. Hammer, co-managing partners of North Run, joined the Company’s Board of Directors following the Company’s 2023 Annual Meeting of Stockholders. Refer to Note 8, Warrant Liabilities , and Note 10, Stockholders' Equity , for more details related to the Private Placement.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2023
Subsequent Events [Abstract]
Subsequent Event	Note 15. Subsequent Event In July 2023, the Company received $ 1,178 for the ERC and $ 57 in interest, which will be recognized in the quarter ended September 30, 2023 along with associated professional fees of $ 177 as reductions to operating expenses.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Accounting Estimates	Accounting Estimates The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes to the condensed financial statements. The accounting estimates that require management’s most significant, difficult and subjective judgments include, but are not limited to, revenue recognition and allowance for expected credit losses, the valuation of notes receivable and inventory, the assessment of recoverability of intangible assets and their estimated useful lives, the valuation and recognition of stock-based compensation, operating lease right-of-use assets and liabilities, the recognition and measurement of current and deferred income tax assets and liabilities, and the valuation of warrant liabilities. Management evaluates its estimates on an ongoing basis as there are changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates. The COVID-19 pandemic and global macroeconomic conditions originating during the pandemic continue to directly and indirectly impact the Company’s business, results of operations and financial condition, including revenue, expenses, reserves and allowances. The Company continues to monitor developments that are highly uncertain, including supply chain disruptions and price increases, as well as the economic impact on domestic and international suppliers, customers, and markets. The Company assessed certain accounting matters that require consideration of forecasted financial information, including, but not limited to, its current expected credit losses, the carrying value of the Company's intangible assets and other long-lived assets, and valuation allowances in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2023 and through the date of this report. As a result of these assessments, there were no impairments or material increases in expected credit losses or valuation allowances that impacted the Company's condensed financial statements as of and for the three and six months ended June 30, 2023 and 2022. However, the Company's future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the condensed financial statements in future reporting periods. As of the date of issuance of these unaudited condensed interim financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”). For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed statements of operations. Warrants issued by the Company that do not meet the criteria for equity treatment are recorded as liabilities. We do not use financial instruments or derivatives for any trading purposes.
Fair Value Measurement	Fair Value Measurement The fair value of the Company’s financial instruments are estimates of the amounts that would be received if the Company were to sell an asset or the Company paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories: • Level 1—based on quoted market prices in active markets for identical assets and liabilities. • Level 2—based on observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3—based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. Fair value measurements are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. The following table sets forth by level, within the fair value hierarchy, the Company's assets and liabilities at fair value as of June 30, 2023: June 30, 2023 Level 1 Level 2 Level 3 Total Assets $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities Warrant derivative liabilities $ — $ — $ 11,602 $ 11,602 Total liabilities $ — $ — $ 11,602 $ 11,602 There were no assets or liabilities measured at fair value as of June 30, 2022. The change in fair value of warrant liabilities measured on a recurring basis using unobservable Level 3 inputs for the quarter ended June 30, 2023 is set forth below: Fair Value at May 18, 2023 Change in Fair Value Fair Value at June 30, 2023 Series A Warrant $ 2,971 $ 3,085 $ 6,056 Series B Warrant 2,634 2,912 5,546 Total warrant liabilities $ 5,605 $ 5,997 $ 11,602 The carrying value of the Company’s cash, cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current liabilities approximate fair value based on the short-term maturities of these instruments. The carrying value of the Company’s notes receivable also approximates fair value based on the associated credit risk. There have been no transfers between levels.
Income Taxes	Income Taxes Income tax expense/(benefit) from continuing operations for the three and six months ended June 30, 2023 and 2022 was $ 0 in each period, which resulted primarily from maintaining a full valuation allowance against the Company’s deferred tax assets. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, certain substantial changes in the Company’s ownership may result in a limitation on the amount of net operating loss and tax credit carryforwards that may be used in future years. The Company has not completed an analysis to determine whether any such limitations have been triggered as of June 30, 2023, however, the Company notes that the Securities Purchase Agreement may have an impact on ownership for purposes of this analysis. Until a study is completed and any limitation known, the Company will not make adjustments to its deferred tax assets. Due to the existence of the valuation allowance, future changes in the Company’s deferred taxes will not impact its effective tax rate or balance sheet.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted The Company reviewed recent pronouncements issued by the FASB and other authoritative standards groups with future effective dates and concluded the pronouncements are either not applicable to the Company or are not expected to have a material impact on the Company’s financial position or results of operations.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2023
Accounting Policies [Abstract]
Schedule of Assets and Liabilities at Fair Value	The following table sets forth by level, within the fair value hierarchy, the Company's assets and liabilities at fair value as of June 30, 2023: June 30, 2023 Level 1 Level 2 Level 3 Total Assets $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities Warrant derivative liabilities $ — $ — $ 11,602 $ 11,602 Total liabilities $ — $ — $ 11,602 $ 11,602
Summary of Change in Fair Value of Warrant Liabilities	The change in fair value of warrant liabilities measured on a recurring basis using unobservable Level 3 inputs for the quarter ended June 30, 2023 is set forth below: Fair Value at May 18, 2023 Change in Fair Value Fair Value at June 30, 2023 Series A Warrant $ 2,971 $ 3,085 $ 6,056 Series B Warrant 2,634 2,912 5,546 Total warrant liabilities $ 5,605 $ 5,997 $ 11,602

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Summary of Product and Service Revenue Disaggregated by Geographic Region	The following table summarizes the Company’s product and service revenue disaggregated by geographic region, which is determined based on customer location, for the three and six months ended June 30, 2023 and 2022: Three Months Ended Six Months Ended 2023 2022 2023 2022 United States $ 7,105 $ 4,097 $ 11,369 $ 8,067 South Korea 16 662 25 2,096 Europe 1,983 956 3,521 2,575 Asia (excluding South Korea) 1,128 771 1,836 1,551 Other 89 137 193 275 Total 1 $ 10,321 $ 6,623 $ 16,944 $ 14,564 1. The table above does not include lease revenue of $ 1,691 and $ 1,415 for three months ended June 30, 2023 and 2022, respectively, and $ 3,320 and $ 2,814 for the six months ended June 30, 2023 and 2022, respectively. Substantially all lease revenue originates from the United States. Refer to Note 5, Leases .
Summary of Information about Receivables and Contract Liabilities from Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers: Classification As of As of Accounts receivable, current Accounts receivable, net $ 3,223 $ 6,040 Notes receivable, current Notes receivable, net $ 595 $ 200 Notes receivable, long-term Notes and other receivables, long-term, net $ 1,221 $ 442 Contract asset, current Prepaid and other current assets $ 825 $ 332 Deferred revenue, current Deferred revenue $ 1,067 $ 768 Deferred revenue, non-current Other long-term liabilities $ 343 $ 17 Contract liability, long-term Other long-term liabilities $ 223 $ 150 The following table provides information about contract assets from contracts with customers: Amount Contract assets as of December 31, 2022 $ 332 Contract assets recognized 889 Payments received ( 250 ) Write-off due to contract modification ( 146 ) Contract assets as of June 30, 2023 $ 825 The following table provides information about contract liabilities from contracts with customers: Amount Contract liabilities as of December 31, 2022 $ 935 Billings not yet recognized as revenue 1,324 Beginning contract liabilities recognized as revenue ( 626 ) Contract liabilities as of June 30, 2023 $ 1,633 Contract liabilities as of December 31, 2021 $ 970 Billings not yet recognized as revenue 637 Beginning contract liabilities recognized as revenue ( 633 ) Contract liabilities as of June 30, 2022 $ 974
Summary of Allowance for Accounts Receivable	The following table summarizes the activity in the allowance for accounts receivable: Amount Accounts receivable, allowance for credit losses as of $ 56 Provision for credit losses ( 26 ) Write-offs — Accounts receivable, allowance for credit losses as of $ 30 Accounts receivable, allowance for credit losses as of $ 47 Provision for credit losses ( 6 ) Write-offs ( 16 ) Accounts receivable, allowance for credit losses as of $ 25
Summary of Allowance for Notes Receivable	The following table summarizes the activity in the allowance for notes receivable: Amount Notes receivable, allowance for credit losses as of $ 13 Provision for credit losses 24 Write-offs — Notes receivable, allowance for credit losses as of $ 37 Notes receivable, allowance for credit losses as of $ 63 Provision for credit losses 130 Write-offs ( 11 ) Notes receivable, allowance for credit losses as of $ 182

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory balances were as follows: As of As of Finished Goods $ 6,303 $ 4,002 Work-in-process 2,753 797 Raw Materials 9,096 6,941 Total $ 18,152 $ 11,740

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2023
Leases [Abstract]
Schedule of Lease Revenue	Lease revenue for the three and six months ended June 30, 2023 and 2022 was as follows: Three Months Ended Six Months Ended 2023 2022 2023 2022 Lease revenue $ 1,691 $ 1,415 $ 3,320 $ 2,814

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Components of Intangible Assets	The components of intangible assets were as follows: As of June 30, 2023 As of December 31, 2022 Gross Accumulated Net Gross Accumulated Net Finite-lived intangible assets: Customer relationships 1,2 $ 4,292 $ ( 2,196 ) $ 2,096 $ 4,292 $ ( 2,028 ) $ 2,264 Acquired technology 1,3,4 13,900 ( 4,425 ) 9,475 13,900 ( 4,042 ) 9,858 Acquired trademarks 1 570 ( 570 ) — 570 ( 570 ) — $ 18,762 $ ( 7,191 ) $ 11,571 $ 18,762 $ ( 6,640 ) $ 12,122 1. Certain intangible assets were established upon PDL BioPharma, Inc.’s acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a period of 15 years. The intangible assets for customer relationships are amortized on a straight-line basis or a double declining basis over their estimated useful lives up to 20 years based on the method that better represents the economic benefits to be obtained. 2. LENSAR acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which are being amortized on a straight-line basis over a period of 10 years. 3. LENSAR acquired certain intangible assets from a medical technology company in an asset acquisition, which are being amortized on a straight-line basis over a period of 15 years. 4. In 2019, LENSAR acquired certain intellectual property from a third party. Pursuant to the Company's agreement with the third party, the Company made milestone payments of $ 2,400 during the year ended December 31, 2022. The intangible assets will be amortized on a straight-line basis over a period of 15 years.
Schedule of Impairment of Underlying Assets, Remaining Amortization Expense	Based on the intangible assets recorded at June 30, 2023, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows: Fiscal Year Amount Remainder of 2023 546 2024 1,125 2025 1,234 2026 1,224 2027 1,215 2028 1,008 Thereafter 5,219 Total remaining estimated amortization expense $ 11,571

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: As of As of Compensation $ 2,369 $ 3,348 Professional services 562 437 Customer advances 90 171 Warranty 184 120 Accrued offering costs 401 — Other 715 624 Total $ 4,321 $ 4,700

Warrant Liabilities (Tables)

Warrant Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of Change in Fair Value of Warrant Liabilities	The change in fair value of warrant liabilities measured on a recurring basis using unobservable Level 3 inputs for the quarter ended June 30, 2023 is set forth below: Fair Value at May 18, 2023 Change in Fair Value Fair Value at June 30, 2023 Series A Warrant $ 2,971 $ 3,085 $ 6,056 Series B Warrant 2,634 2,912 5,546 Total warrant liabilities $ 5,605 $ 5,997 $ 11,602
Summary of Estimated Fair Value Assumptions of Warrant Liabilities	The fair value of the warrant liabilities was estimated using the following assumptions for the three and six months ended June 30, 2023 and 2022: June 30, 2023 May 18, 2023 Risk-free interest rate 4.1 % 3.7 % Expected term (years) 4.9 5.0 Expected volatility 55 % 55 % Dividends 0.0 % 0.0 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2023
Summary of Shares Available for Issuance Under 2020 Plan	A summary of the shares available for issuance under the 2020 Plan is as follows: Number of Shares Balance at December 31, 2022 1,002 Authorized 555 Granted/Awarded ( 1,368 ) Cancelled 68 Balance at June 30, 2023 257
Summary of Option Award Activity	Option award activity under the 2020 Plan is set forth below: Options Outstanding Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (In Years) Aggregate Intrinsic Value Outstanding at December 31, 2022 1,202 $ 6.91 8.7 $ — Options granted 826 $ 2.97 Options exercised — $ — Options cancelled ( 32 ) $ 5.60 Outstanding at June 30, 2023 1,996 $ 5.30 8.8 $ 1,037 Vested and expected to vest at June 30, 2023 1,996 $ 5.30 8.8 $ 1,037 Vested and exercisable at June 30, 2023 710 $ 7.01 8.1 $ 23
Summary of Stock Options Outstanding and Vested	The following table summarizes information about stock options outstanding and vested as of June 30, 2023: Options Outstanding Options Vested Exercise Price Options Outstanding Weighted Average Remaining Contractual Term (in Years) Weighted Average Exercise Price Number Exercisable Weighted Average Exercise Price $ 2.52 - $ 3.10 360 9.5 $ 2.66 — $ — $ 3.23 455 9.9 $ 3.23 22 $ 3.23 $ 4.86 - $ 5.95 27 9.0 $ 5.75 4 $ 5.95 $ 6.04 418 8.5 $ 6.04 148 $ 6.04 $ 6.07 - $ 8.62 736 7.9 $ 7.44 536 $ 7.44 1,996 8.8 $ 5.30 710 $ 7.01
Summary of Fair Value of Stock Options was Estimated Using Assumptions	The fair value of stock options was estimated using the following assumptions for the three and six months ended June 30, 2023 and 2022: Three Months Ended Six Months Ended 2023 2022 2023 2022 Risk-free interest rate 3.5 - 3.9 % 2.5 - 3.0 % 3.5 - 4.2 % 1.5 - 3.0 % Expected term (years) 6 6 6 6 Expected volatility 70 % 70 % 70 % 70 % Dividends 0.0 % 0.0 % 0.0 % 0.0 %
Summary of Total Stock-Based Compensation Expense Recognized	The following table sets forth the total stock-based compensation expense recognized under the 2020 Plan and the 2020 ESPP in the Company's condensed statements of operations: Three Months Ended Six Months Ended 2023 2022 2023 2022 Cost of revenue – product $ 87 $ 54 $ 170 $ 106 Cost of revenue – service 50 32 96 62 Selling, general and administrative expenses 1,498 1,397 2,924 2,774 Research and development expenses 189 154 360 302 Total $ 1,824 $ 1,637 $ 3,550 $ 3,244
Summary of Unrecognized Stock-based Compensation Expense Expected to be Amortized	Total unrecognized stock-based compensation expense is expected to be amortized as follows: Fiscal Year Amount Remainder of 2023 $ 1,910 2024 2,124 2025 1,005 2026 213 2027 5 Total unrecognized stock-based compensation expense $ 5,257
Restricted Stock Awards
Summary of Restricted Stock Award Activity	Restricted stock award activity under the 2020 Plan is set forth below: Restricted Stock Awards Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2022 622 $ 10.29 Restricted stock awards granted — $ — Restricted stock awards vested ( 373 ) $ 10.20 Restricted stock awards cancelled ( 6 ) $ 10.81 Non-vested at June 30, 2023 243 $ 10.42
Restricted Stock Units
Summary of Restricted Stock Award Activity	Restricted stock unit activity under the 2020 Plan is set forth below: Restricted Stock Units Outstanding Number of Units Weighted Average Grant Date Fair Value Per Share Non-vested at December 31, 2022 86 $ 6.33 Restricted stock units granted 542 $ 2.73 Restricted stock units vested ( 41 ) $ 6.65 Restricted stock units cancelled ( 30 ) $ 2.65 Non-vested at June 30, 2023 557 $ 3.00

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share	The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the basic and diluted net loss per share calculations: Three Months Ended Six Months Ended 2023 2022 2023 2022 Net loss $ ( 8,753 ) $ ( 6,759 ) $ ( 13,025 ) $ ( 13,433 ) Weighted average number of shares of common stock 10,820 10,073 10,768 10,020 Basic and diluted net loss per common share $ ( 0.81 ) $ ( 0.67 ) $ ( 1.21 ) $ ( 1.34 )
Schedule of Antidilutive Securities Excluded From Calculation of Net Loss Per Share Diluted Shares	The Company excluded the following amounts of equity securities from its net loss per diluted share calculations for the periods presented because their effect was anti-dilutive: Three and Six Months Ended June 30, 2023 2022 Series A Redeemable Convertible Preferred Stock 7,940 — Series A and Series B Warrants 4,367 — Restricted stock awards and units 800 934 Outstanding stock options 1,996 1,193
Schedule of Anti-Dilutive Weighted Average Shares Excluded From Diluted Net Loss Per Share Diluted Shares Calculation	The anti-dilutive weighted average shares excluded from the diluted net loss per share diluted shares calculations were:

Overview and Basis of Present_2

Overview and Basis of Presentation - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Overview And Basis Of Presentation [Line Items]
Accumulated deficit	$ (110,533)	$ (97,508)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of assets and liabilities at fair value (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2022
Assets
Total assets		$ 0
Liabilities
Warrant derivative liabilities	$ 11,602,000
Total liabilities	11,602,000	$ 0
Level 3
Liabilities
Warrant derivative liabilities	11,602,000
Total liabilities	$ 11,602,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Accounting Policies [Abstract]
Assets measured at fair value		$ 0		$ 0
Liabilities measured at fair value	$ 11,602,000	0	$ 11,602,000	0
Income tax expense/(benefit) from continuing operations	$ 0	$ 0	$ 0	$ 0

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Change in Fair Value of Warrant Liabilities (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023	Jun. 30, 2023
Class of Warrant or Right [Line Items]
Change in fair value of warrant liabilities		$ 5,997	$ 5,997
Level 3
Class of Warrant or Right [Line Items]
Fair value, beginning balance	$ 5,605
Change in fair value of warrant liabilities	5,997
Fair value, ending balance	11,602	11,602	11,602
Series A Warrants | Level 3
Class of Warrant or Right [Line Items]
Fair value, beginning balance	2,971
Change in fair value of warrant liabilities	3,085
Fair value, ending balance	6,056	6,056	6,056
Series B Warrants | Level 3
Class of Warrant or Right [Line Items]
Fair value, beginning balance	2,634
Change in fair value of warrant liabilities	2,912
Fair value, ending balance	$ 5,546	$ 5,546	$ 5,546

Revenue From Contracts With C_3

Revenue From Contracts With Customers - Summary of Product and Service Revenue Disaggregated by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Product and service revenue	$ 10,321	$ 6,623	$ 16,944	$ 14,564
United States
Disaggregation Of Revenue [Line Items]
Product and service revenue	7,105	4,097	11,369	8,067
South Korea
Disaggregation Of Revenue [Line Items]
Product and service revenue	16	662	25	2,096
Europe
Disaggregation Of Revenue [Line Items]
Product and service revenue	1,983	956	3,521	2,575
Asia (Excluding South Korea)
Disaggregation Of Revenue [Line Items]
Product and service revenue	1,128	771	1,836	1,551
Other
Disaggregation Of Revenue [Line Items]
Product and service revenue	$ 89	$ 137	$ 193	$ 275

Revenue From Contracts With C_4

Revenue From Contracts With Customers - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue From Contracts With Customers [Line Items]
Lease revenue	$ 1,691	$ 1,415	$ 3,320	$ 2,814
Accounts receivables payment terms			30 days
Interest income on notes receivable	20	$ 3	$ 32	$ 8
Revenue remaining performance obligation amount	$ 15,705		$ 15,705
Minimum
Revenue From Contracts With Customers [Line Items]
Notes receivable interest rate	5%		5%
Maximum
Revenue From Contracts With Customers [Line Items]
Notes receivable interest rate	7%		7%

Revenue From Contracts With C_5

Revenue From Contracts With Customers - Summary of Information about Receivables and Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Schedule Of Contract Balances [Line Items]
Accounts receivable, current	$ 3,223	$ 6,040
Notes receivable, current	595	200
Notes receivable, long-term	1,221	442
Deferred revenue, current	1,067	768
Contract liability, current	1,067	768
Notes and Other Receivables, Long-Term, Net
Schedule Of Contract Balances [Line Items]
Notes receivable, long-term	1,221	442
Prepaid and Other Current Assets
Schedule Of Contract Balances [Line Items]
Contract asset, current	825	332
Other Long-Term Liabilities
Schedule Of Contract Balances [Line Items]
Deferred revenue, non-current	343	17
Contract liability, non-current	$ 223	$ 150

Revenue From Contracts With C_6

Revenue From Contracts With Customers - Summary of Allowance for Accounts Receivable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 56	$ 47
Provision for credit losses	(26)	(6)
Write-offs	0	(16)
Ending balance	$ 30	$ 25

Revenue From Contracts With C_7

Revenue From Contracts With Customers - Summary of Allowance for Notes Receivable (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 13	$ 63
Provision for credit losses	24	130
Write-offs	0	(11)
Ending balance	$ 37	$ 182

Revenue From Contracts With C_8

Revenue From Contracts With Customers - Schedule of Information About Contract Assets from Contracts with Customers (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Revenue from Contract with Customer [Abstract]
Beginning Balance	$ 332
Contract assets recognized	889
Payments received	(250)
Write-off due to contract modification	(146)
Ending Balance	$ 825

Revenue From Contracts With C_9

Revenue From Contracts With Customers - Schedule of Information About Contract Liabilities from Contracts with Customers (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Revenue from Contract with Customer [Abstract]
Beginning balance	$ 935	$ 970
Billings not yet recognized as revenue	1,324	637
Beginning contract liabilities recognized as revenue	(626)	(633)
Ending balance	$ 1,633	$ 974

Revenue From Contracts With _10

Revenue From Contracts With Customers - Additional Information (Details 1) $ in Thousands	Jun. 30, 2023 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 15,705
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-07-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 3,155
Revenue remaining performance obligation expected timing of satisfaction period	6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 4,704
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 3,687
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 2,194
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 1,361
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 486
Revenue remaining performance obligation expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2029-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue remaining performance obligation amount	$ 118
Revenue remaining performance obligation expected timing of satisfaction period

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventory, Net [Abstract]
Finished Goods	$ 6,303	$ 4,002
Work-in-process	2,753	797
Raw Materials	9,096	6,941
Total	$ 18,152	$ 11,740

Leases - Additional Information

Leases - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023
Minimum
Lessee and Lessor Lease Description [Line Items]
Lessor, operating leases, remaining lease terms	1 year
Maximum
Lessee and Lessor Lease Description [Line Items]
Lessor, operating leases, remaining lease terms	6 years

Leases - Schedule of Lease Reve

Leases - Schedule of Lease Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Leases [Abstract]
Lease revenue	$ 1,691	$ 1,415	$ 3,320	$ 2,814

Intangible Assets - Components

Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 18,762	$ 18,762
Accumulated Amortization	(7,191)	(6,640)
Net Carrying Amount	11,571	12,122
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,292	4,292
Accumulated Amortization	(2,196)	(2,028)
Net Carrying Amount	2,096	2,264
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	13,900	13,900
Accumulated Amortization	(4,425)	(4,042)
Net Carrying Amount	9,475	9,858
Acquired Trademarks
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	570	570
Accumulated Amortization	(570)	(570)
Net Carrying Amount	$ 0	$ 0

Intangible Assets - Component_2

Intangible Assets - Components of Intangible Assets (Parenthetical) (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2019	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	15 years
Customer Relationships
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	10 years
Acquired Technology
Finite Lived Intangible Assets [Line Items]
Acquired intangible assets weighted average amortization period	15 years	15 years
Contingent milestone payments			$ 2,400
Maximum | Customer Relationships
Finite Lived Intangible Assets [Line Items]
Intangible assets estimated useful life	20 years

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 275	$ 287	$ 551	$ 596

Intangible Assets - Schedule of

Intangible Assets - Schedule of Impairment of Underlying Assets, Remaining Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2023	$ 546
2024	1,125
2025	1,234
2026	1,224
2027	1,215
2028	1,008
Thereafter	5,219
Net Carrying Amount	$ 11,571	$ 12,122

Accrued Liabilities - Schedule

Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Compensation	$ 2,369	$ 3,348
Professional services	562	437
Customer advances	90	171
Warranty	184	120
Accrued offering costs	401
Other	715	624
Total	$ 4,321	$ 4,700

Warrant Liabilities - Additiona

Warrant Liabilities - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		6 Months Ended
	May 31, 2023	Jun. 30, 2023
Class of Warrant or Right [Line Items]
Warrants to purchase aggregate shares of common stock	4,367
Warrant liability percentage of floor on volatility input		100%
Gross proceeds for the Private Placement		$ 20,000
Proceeds from issuance of warrants		5,605
Proceeds from issuance of series A redeemable convertible preferred stock		$ 14,395
Series A Warrants
Class of Warrant or Right [Line Items]
Percentage of warrants	50%
Exercise price of warrants	$ 2.45
Series B Warrants
Class of Warrant or Right [Line Items]
Percentage of warrants	50%
Exercise price of warrants	$ 3.0625

Warrant Liabilities - Summary o

Warrant Liabilities - Summary of Estimated Fair Value Assumptions of Warrant Liabilities (Details)		3 Months Ended	6 Months Ended
	May 18, 2023	Jun. 30, 2023	Jun. 30, 2023
Class of Warrant or Right [Line Items]
Risk-free interest rate	3.70%	4.10%	4.10%
Expected term (years)	5 years	4 years 10 months 24 days	4 years 10 months 24 days
Expected volatility	55%	55%	55%
Dividends	0%	0%	0%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Commitments And Contingencies Disclosure [Line Items]
Employee retention credit amount	$ 1,600,000
Contingent professional fees	250,000
Employee retention credit amount recognized	$ 0
Additional royalty payments rate	3%
Supply Agreement
Commitments And Contingencies Disclosure [Line Items]
Purchase obligation	$ 8,959,000

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($)		6 Months Ended
	May 31, 2023	Jun. 30, 2023
Convertible Preferred Stock [line Items]
Offering costs		$ 901,000
General and administrative expenses
Convertible Preferred Stock [line Items]
Offering costs		253,000
Securities Purchase Agreement | Minimum
Convertible Preferred Stock [line Items]
Sale of ownership percentage	50%
Series A Redeemable Convertible Preferred Stock
Convertible Preferred Stock [line Items]
Offering costs		$ 648,000
Series A Redeemable Convertible Preferred Stock | Securities Purchase Agreement
Convertible Preferred Stock [line Items]
Aggregate purchase price of shares	$ 20,000
Aggregate shares	20
Number of shares convertible into common stock	7,940

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)			3 Months Ended		6 Months Ended
	May 31, 2023	Apr. 08, 2021	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, shares issued			0		0		0
Preferred stock, shares outstanding			0		0		0
Common stock voting rights					The Company has a single class of common stock in which stockholders are entitled to one vote for each share of common stock
Cash dividend declared on common stock			$ 0	$ 0	$ 0	$ 0
Maximum value of common and preferred stock and other securities issuable		$ 100,000,000
Securities Purchase Agreement | Series A Redeemable Convertible Preferred Stock
Class of Stock [Line Items]
Aggregate purchase price of shares	$ 20,000
Aggregate shares	20
Number of shares convertible into common stock	7,940
Minimum | Securities Purchase Agreement
Class of Stock [Line Items]
Sale of ownership percentage	50%
ATM offerings
Class of Stock [Line Items]
Issuance of common stock, Shares			0	0	0	0
ATM offerings | Maximum
Class of Stock [Line Items]
Aggregate amount offered, issuance and sale by the Company		$ 35,000,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Jul. 31, 2020	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted average grant date fair value of options granted		$ 2.1		$ 1.94
Total fair value of options vested		$ 604		$ 1,794
Total unrecognized compensation expense		$ 3,409		$ 3,409
Total unrecognized compensation expense, weighted-average period of recognition				2 years 3 months 18 days
Dividends		0%	0%	0%	0%
Common stock, shares authorized		150,000,000		150,000,000				150,000,000
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved		216		216
Percentage of outstanding shares of common stock				1%
Exercise price of option on fair value (as a percent)				85%
Common stock, shares authorized		451,000		451,000					340,000
Shares of common stock have been issued to employees				235
Incentive Stock Options | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting percentage				10%
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation expense, weighted-average period of recognition				1 month 6 days
Total fair value of restricted stock awards vested		$ 1,387		$ 3,806
Total unrecognized compensation expense		498		498
Restricted Stock Awards | Forecast
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of restricted stock awards are expected to vest						75,000	168,000
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of restricted stock units vested		$ 180		$ 271
Minimum | Incentive Stock Options And Nonqualified Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				1 year
Minimum | Incentive Stock Options And Nonqualified Stock Options | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of option on fair value (as a percent)				100%
Minimum | Incentive Stock Options | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of option on fair value (as a percent)				110%
Minimum | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				1 year
Maximum | Incentive Stock Options And Nonqualified Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of contract				10 years
Vesting period				4 years
Maximum | Incentive Stock Options And Nonqualified Stock Options | Share-based Payment Arrangement, Tranche One
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of contract				10 years
Maximum | Incentive Stock Options | Share-based Payment Arrangement, Tranche Two
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Term of contract				5 years
Maximum | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period				4 years
2020 Incentive Award Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved	3,333,000	4,984,000		4,984,000
Percentage of outstanding shares of common stock	5%
2020 Incentive Award Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation expense		$ 1,350		$ 1,350
Total unrecognized compensation expense, weighted-average period of recognition				1 year 8 months 12 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Shares Available for Issuance Under 2020 Plan (Details) - 2020 Incentive Award Plan	6 Months Ended
	Jun. 30, 2023 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Balance	1,002
Authorized	555
Granted/Awarded	(1,368)
Cancelled	68
Balance	257

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Option Award Activity (Details) - 2020 Incentive Award Plan - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at December 31, 2022	1,202,000
Options granted	826,000
Options cancelled	(32,000)
Outstanding at June 30, 2023	1,996,000	1,202,000
Vested and expected to vest at June 30, 2023	1,996,000
Vested and exercisable at June 30, 2023	710,000
Outstanding at beginning of period, Weighted Average Exercise Price	$ 6.91
Options granted, Weighted Average Exercise Price	2.97
Options cancelled, Weighted Average Exercise Price	5.6
Outstanding at end of period, Weighted Average Exercise Price	5.3	$ 6.91
Vested and expected to vest at June 30, 2023, Weighted Average Exercise Price	5.3
Vested and exercisable at June 30, 2023, Weighted Average Exercise Price	$ 7.01
Options Outstanding, Weighted Average Remaining Contractual Term (in Years)	8 years 9 months 18 days	8 years 8 months 12 days
Vested and expected to vest at June 30, 2023, Weighted Average Remaining Contractual Term (in Years)	8 years 9 months 18 days
Vested and exercisable at June 30, 2023, Weighted Average Remaining Contractual Term (in Years)	8 years 1 month 6 days
Outstanding at June 30, 2023, Aggregate Intrinsic Value	$ 1,037
Vested and expected to vest at June 30, 2023, Aggregate Intrinsic Value	1,037
Vested and exercisable at June 30, 2023, Aggregate Intrinsic Value	$ 23

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock Options Outstanding And Vested (Details)	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	1,996,000
Options outstanding, Weighted average remaining contractual term (in years)	8 years 9 months 18 days
Options outstanding, Weighted average exercise price	$ 5.3
Options vested, Number Exercisable | shares | shares	710,000
Options vested, Weighted average exercise price	$ 7.01
Exercise Price $2.52 - $3.10
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	360,000
Options outstanding, Weighted average remaining contractual term (in years)	9 years 6 months
Options outstanding, Weighted average exercise price	$ 2.66
Exercise Price $2.52 - $3.10 | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price range (lower)	2.52
Exercise price range (upper)	$ 3.1
Exercise Price $3.23
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	455,000
Options outstanding, Weighted average remaining contractual term (in years)	9 years 10 months 24 days
Options outstanding, Weighted average exercise price	$ 3.23
Options vested, Number Exercisable | shares | shares	22,000
Options vested, Weighted average exercise price	$ 3.23
Exercise Price $3.23 | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price range (lower)	$ 3.23
Exercise Price $4.86 - $5.95
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	27,000
Options outstanding, Weighted average remaining contractual term (in years)	9 years
Options outstanding, Weighted average exercise price	$ 5.75
Options vested, Number Exercisable | shares | shares	4,000
Options vested, Weighted average exercise price	$ 5.95
Exercise Price $4.86 - $5.95 | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price range (lower)	4.86
Exercise price range (upper)	$ 5.95
Exercise Price $6.04
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	418,000
Options outstanding, Weighted average remaining contractual term (in years)	8 years 6 months
Options outstanding, Weighted average exercise price	$ 6.04
Options vested, Number Exercisable | shares | shares	148,000
Options vested, Weighted average exercise price	$ 6.04
Exercise Price $6.04 | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price range (lower)	$ 6.04
Exercise Price $6.07 - $8.62
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, Number | shares	736,000
Options outstanding, Weighted average remaining contractual term (in years)	7 years 10 months 24 days
Options outstanding, Weighted average exercise price	$ 7.44
Options vested, Number Exercisable | shares | shares	536,000
Options vested, Weighted average exercise price	$ 7.44
Exercise Price $6.07 - $8.62 | Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price range (lower)	6.07
Exercise price range (upper)	$ 8.62

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Fair Value of Employee and Non-Employee Stock Options was Estimated Using Assumptions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate, minimum	3.50%	2.50%	3.50%	1.50%
Risk-free interest rate, maximum	3.90%	3%	4.20%	3%
Expected term (years)	6 years	6 years	6 years	6 years
Expected volatility	70%	70%	70%	70%
Dividends	0%	0%	0%	0%

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of Restricted Stock Award Activity (Details) - Restricted Stock Awards - 2020 Incentive Award Plan shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2022 | shares	622
Restricted stock awards vested | shares	(373)
Restricted stock awards cancelled | shares	(6)
Non-vested at June 30, 2023 | shares	243
Non-vested at December 31, 2022 | $ / shares	$ 10.29
Restricted stock awards vested | $ / shares	10.2
Restricted stock awards cancelled | $ / shares	10.81
Non-vested at June 30, 2023 | $ / shares	$ 10.42

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Restricted Stock Units Activity (Details) - Restricted Stock Units - 2020 Incentive Award Plan shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Non-vested at December 31, 2022 | shares	86
Restricted stock awards granted | shares	542
Restricted stock awards vested | shares	(41)
Restricted stock units cancelled | shares	(30)
Non-vested at June 30, 2023 | shares	557
Non-vested at December 31, 2022 | $ / shares	$ 6.33
Restricted stock awards granted | $ / shares	2.73
Restricted stock awards vested | $ / shares	6.65
Restricted stock awards cancelled | $ / shares	2.65
Non-vested at June 30, 2023 | $ / shares	$ 3

Stock-Based Compensation - Su_7

Stock-Based Compensation - Summary of Total Stock-Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,824	$ 1,637	$ 3,550	$ 3,244
Cost of Sales | Product
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	87	54	170	106
Cost of Sales | Service
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	50	32	96	62
Selling, General and Administrative Expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,498	1,397	2,924	2,774
Research and Development Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 189	$ 154	$ 360	$ 302

Stock-Based Compensation - Su_8

Stock-Based Compensation - Summary of Unrecognized Stock-based Compensation Expense Expected to be Amortized (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Remainder of 2023	$ 1,910
2024	2,124
2025	1,005
2026	213
2027	5
Total unrecognized stock-based compensation expense	$ 5,257

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Abstract]
Net loss	$ (8,753)	$ (6,759)	$ (13,025)	$ (13,433)
Weighted average number of shares of common stock basic	10,820	10,073	10,768	10,020
Weighted average number of shares of common stock diluted	10,820	10,073	10,768	10,020
Basic net loss per common share	$ (0.81)	$ (0.67)	$ (1.21)	$ (1.34)
Diluted net loss per common share	$ (0.81)	$ (0.67)	$ (1.21)	$ (1.34)

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2023
Earnings Per Share [Abstract]
Change in fair value of warrant liabilities	$ 5,997	$ 5,997

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Gross Anti-Dilutive Securities Excluded From Net Loss Per Share Diluted Shares Calculation (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Series A Redeemable Convertible Preferred Stock
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	7,940		7,940
Series A and Series B Warrants
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	4,367		4,367
Restricted Stock Awards and Units
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	800	934	800	934
Outstanding Stock Options
Earnings Per Share Basic [Line Items]
Shares excluded from the calculation of net loss per diluted share	1,996	1,193	1,996	1,193

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Anti-Dilutive Weighted Average Shares Excluded From Diluted Net Loss Per Share Diluted Shares Calculation (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	7,275	2,135	9,264	2,129
Series A Redeemable Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	7,940		7,940
Series A Redeemable Convertible Preferred Stock | Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	4,188		6,054
Series A Warrants | Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	352		508
Series B Warrants | Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	152		219
Restricted Stock Awards and Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	800	934	800	934
Restricted Stock Awards and Units | Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	851	995	859	1,033
Outstanding Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	1,996	1,193	1,996	1,193
Outstanding Stock Options | Weighted Average
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Weighted average shares excluded from the calculation of net loss per diluted share	1,732	1,140	1,624	1,096

Subsequent Event - Additional I

Subsequent Event - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended
	Jul. 31, 2023	Sep. 30, 2023	Jun. 30, 2023
Subsequent Event [Line Items]
Employee retention credit amount			$ 1,600
Forecast
Subsequent Event [Line Items]
Interest to be recognized		$ 57
Associated professional fees to be recognized		$ 177
Subsequent Event
Subsequent Event [Line Items]
Employee retention credit amount	$ 1,178